ODAC to review Avastin sBLAs

Roche (SIX:ROG; OTCQX:RHHBY) said FDA's Oncologic Drugs Advisory Committee will meet on July 20 to discuss a pair of sBLAs for Avastin bevacizumab to treat advanced HER2-negative breast cancer in combination with docetaxel, or with taxane-, anthracycline- or capecitabine-based chemotherapy. Both applications have a PDUFA date of Sept. 17. ...